IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).

JOURNAL OF CLINICAL ONCOLOGY

LIPPINCOTT WILLIAMS & WILKINS

1. F. Hoffmann-La Roche, Ltd